Liver transplantation (LT) improves daily function and cognition in patients with cirrhosis, but a subset of patients can remain impaired. Unfavorable microbiota or dysbiosis is observed in patients with cirrhosis, but the effect of LT on microbial composition, especially with poor post-LT cognition, is unclear. The aims were to determine the effect of LT on gut microbiota and to determine whether gut microbiota are associated with cognitive dysfunction after LT. We enrolled outpatient patients with cirrhosis on the LT list and followed them until 6 months after LT. Cognition (Psychometric Hepatic Encephalopathy score [PHES]), health-related quality of life (HRQOL), and stool microbiota (multitagged sequencing for diversity and taxa) tests were performed at both visits. Persistent cognitive impairment was defined as a stable/worsening PHES. Both pre-/post-LT data were compared with age-matched healthy controls. We enrolled 45 patients (56 6 7 years, Model for End-Stage Liver Disease score 26 6 8). They received LT 6 6 3 months after enrollment and were re-evaluated 7 6 2 months after LT with a stable course. A significantly improved HRQOL, PHES, with increase in microbial diversity, increase in autochthonous, and decrease in potentially pathogenic taxa were seen after LT compared with baseline. However, there was continued dysbiosis and HRQOL/cognitive impairment after LT compared with controls in 29% who did not improve PHES after LT. In these, Proteobacteria relative abundance was significantly higher and Firmicutes were lower after LT, whereas the reverse occurred in the group that improved. Delta PHES was negatively correlated with delta Proteobacteria and positively with delta Firmicutes. In conclusion, LT improves gut microbiota diversity and dysbiosis compared with pre-LT baseline but residual dysbiosis remains compared with controls. There is cognitive and HRQOL enhancement in general after LT, but a higher Proteobacteria relative abundance change is associated with posttransplant cognitive impairment.
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Liver transplantation (LT) is associated with an overall medical and functional recovery for most patients, but a subset of patients has cognitive impairment and difficulties with health-related quality of life (HRQOL) even after this procedure.
(1) The determinants of this continuing dysfunction in cognition and HRQOL are relevant because they can help define the approach and counseling methods to the patients and their caregivers in the pre-LT setting. (2) Pre-LT gut microbiota, especially in phylum Proteobacteria (includes Escherichia, Klebsiella), are linked with poor outcomes such as cognitive impairment, readmissions, and mortality. (3) (4) (5) (6) (7) Prior human and animal studies have shown that LT can variably impact gut microbiota. These studies, however, are either focused on perioperative outcomes, employ focused methods to detect microbiota, have a relatively small sample size longitudinally, or are cross-sectional in nature. (8) (9) (10) (11) (12) Trials focused on beneficial microbial modulation in this population have shown variable benefit. (13) However, the longitudinal changes in gut microbial composition and their association with post-LT cognitive improvement are unclear.
Our hypothesis was that LT is associated with a significant improvement in gut microbial dysbiosis in cirrhosis, which is linked with the extent of cognitive impairment.
The aims of this study were to determine the effect of LT on gut microbiota by comparing post-LT microbiota with pre-LT baseline and with an agematched group of healthy controls and to determine whether gut microbiota changes are associated with cognitive dysfunction after LT.
Patients and Methods
Patients with cirrhosis were enrolled if they were outpatients listed for LT on the deceased donor list at Virginia Commonwealth University Medical Center between June 2011 and June 2015. Included patients were between 21 and 65 years old, able to provide consent and samples, as well as understand English. We excluded those who were listed as status 1, had chronic neurological diseases, were unwilling to consent or provide samples, had human immunodeficiency virus (HIV), or were unlikely to followup.
All patients gave informed consent, which was followed by cognitive testing using the validated Psychometric Hepatic Encephalopathy score (PHES; range 215 to 14, with higher score indicating better cognitive performance). (14, 15) Cognitive impairment or minimal hepatic encephalopathy (MHE) was diagnosed with a total score of 4. (14) This was followed by HRQOL testing with Sickness Impact Profile (SIP). (16) The SIP has 136 questions that have 2 domains, physical and psychosocial, and 12 subcategories. A high score indicates worse HRQOL. A 24-hour dietary recall was performed. Stool for gut microbiota analysis was collected on the same day. DNA was extracted for multitagged sequencing using published techniques. (5) An age-matched group of healthy controls without chronic diseases was also recruited; these patients also underwent similar cognitive, HRQOL, and microbiota testing.
Patients with cirrhosis who were participating were then followed until LT, death on the waiting list, or delisting. For those who underwent transplantation, the details of the LT surgery, immunosuppression regimen, hospitalizations, rejection episodes, duration of hospital stay, and need for relisting was recorded. The posttransplant visit was performed at after 6 months for patients who were alive and willing and who had not undergone a second transplant or were listed for another transplant (including renal transplant). We chose this posttransplant timeframe to avoid immediate and transient postoperative complications. (17) At 6 months, all procedures performed at the baseline visit were repeated.
Changes in cognition and HRQOL were compared within groups using paired t tests (pre-LT versus post-LT groups) and compared with controls using unpaired t tests. Persistent cognitive impairment was defined as a stable or worsening PHES score; any improvement in PHES was considered cognitive improvement. MHE was diagnosed on PHES based on local norms, and reversal of MHE was also noted after LT. On the basis of our prior studies, the rate of impairment was assumed to be 50% before LT reduced to 20% after LT. The rate of dysbiosis hypothesized is present in 60%-75% of patients with cognitive impairment. Therefore, using a power of 0.8 and alpha of 0.05 for a 75% rate of dysbiosis to detect dysbiosis change from 37.5% before LT to 15% after LT, we would require 31 subject pairs (pre-/post-LT patients), whereas for a 60% rate of dysbiosis (30% before LT to 12% after LT), we would require 43 subject pairs.
ANALYSIS OF MICROBIOTA
Stool was analyzed for microbiota composition using 16s ribosomal RNA (V1-V2) sequencing using multitag sequencing on an Ion Torrent PGM. (5) The microbiota relative abundance was analyzed using a diversity analysis, Wilcoxon paired tests, and Linear Discriminant Analysis Effect Size (LEFSe) between and within groups. (18, 19) The microbiota analysis was performed between the groups (pre-LT, post-LT, and control groups) as a whole and then between groups that improved cognitively versus those who did not improve. The Chao1 index was used to define alphadiversity in groups; analysis was performed using paired Wilcoxon tests within different time points (pre-LT versus post-LT patients) and using Mann-Whitney U tests between groups (compared to controls). The taxa seen more in the pre-LT group belong to Bacteroidaceae, Enterobacteriaceae (Klebsiella, Enterobacter), Lactobacillaceae and Veillonellacae. Taxa seen more in controls belong to Lachnospiraceae, Ruminococcaceae, Clostridiales Cluster XIV, Streptococcaceae, Synergisticeae, and Desulfovibrioceae. (C) Cladogram showing differences between the post-LT group (green) compared with healthy controls (red). The taxa seen more in the post-LT group belong to Bacteroidaceae, Bradyrhizobiaceae, and Veillonellacae. Taxa seen more in controls belong to Lachnospiraceae, Ruminococcaceae, Clostridiales Cluster XIV, Streptococcaceae, Eubacteriaceae, and Bifidobacteriaceae.
LIVER TRANSPLANTATION, Vol. 23, No. 7, 2017 BAJAJ ET AL.
Results
We enrolled 68 patients, of whom 8 died on the waiting list, 7 were delisted, and 3 were not able to provide stool samples. The remaining 50 underwent transplantation, of whom 45 were seen after LT. Of the remaining 5, 2 died within 1 month of LT, 1 required retransplantation due to primary nonfunction, and 2 were lost to follow-up. The 45 patients with cirrhosis finally enrolled included 32 men who had a mean age of 56 6 7 years and Model for End-Stage Liver Disease score on enrollment of 26 6 8. The majority had hepatitis C virus (HCV; n 5 21) followed by nonalcoholic fatty liver disease (n 5 12), alcoholic liver disease (n 5 10), and others (n 5 2). Most patients had evidence of hepatic encephalopathy (HE; 25 on lactulose and an additional 9 on rifaximin). Ten patients were listed for hepatocellular cancer that was under locoregional control. Patients received LT 6 6 3 months after enrollment and were reevaluated 7 6 2 months after LT for their second visit.
In these 45 patients, 2 patients had developed rejection treated with steroids within the first 3 months, 8 developed infections (C. difficile in 4 and biliary sepsis in 3 and surgical wound infection in 2; 1 person had both biliary sepsis and C. difficile), and 4 required biliary manipulation. An additional 2 patients required elective inguinal hernia repair and 1 person developed delirium that was treated by reducing the steroid dose. All these issues were resolved for more than 2 months before their post-LT visit. Five patients were on dialysis before LT and remained on it during the post-LT visit. At the time of the post-LT visit, all patients were alert and oriented, none had recurrent cirrhosis or HE, or were on antibiotics other than trimethoprim-sulfomethoxazole.
The immunosuppression followed our standard protocol which is steroids tapered over 1 month with mycophenolate mofetil initiated perioperatively. Tacrolimus is started at day 3 to maintain levels between 8 and 12 ng/mL for the first 3 months and between 5 and 10 ng/mL after that period depending on the cirrhosis etiology. Regular tacrolimus trough levels were monitored throughout, and all patients were within the proscribed trough range (10.5 6 4.9 ng/mL average tacrolimus level prior to 6-month visit). None of the HCV patients had sustained virological response pretransplant and did not receive any anti-HCV therapy before the posttransplant testing due to the relative novelty and the lack of experience in peritransplant HCV direct antiviral therapy at the time of study recruitment. No new antidepressant or antianxiety medications were initiated after LT. All patients were nonvegetarians without any specific dietary restrictions. There was no significant change in total caloric intake before and after LT (before LT 2186 6 345 versus after LT 2381 6 236 Kcal).
MICROBIAL CHANGES BEFORE/AFTER LT
There was a significant increase in diversity (Chao1, pre-LT patients 468.9 6 263.1 versus post-LT patients 694.9 6 240.6; P < 0.05) after LT. At a phylum level, there was no change in relative abundance of taxa per se (Firmicutes, pre-LT patients 37% versus 53% post-LT patients, P 5 0.83; Bacteroidetes, pre-LT patients 53% versus 37% post-LT patients, P 5 0.61; Proteobacteria, pre-LT patients 1.3% versus 1.6% post-LT patients, P 5 0.65). However, on LEFSe analysis, there was a reduction in potentially pathogenic genera belonging to Enterobacteriaceae (Escherichia, Shigella, Salmonella) with a significant increase in potentially beneficial, autochthonous taxa, ie, Ruminococcaceae and Lachnospiraceae (Fig. 1A) .
COMPARISON WITH HEALTHY CONTROLS
Healthy controls had a mean age of 55 6 6 years. As expected, controls had the best cognitive performance and HRQOL, even when compared with post-LT patients (Table 1) .
Controls had the highest diversity (Chao1, 772.1 6 254.2; P < 0.05), which was significantly higher compared with pre-LT patients but only trended higher compared with post-LT patients. When compared with controls, higher pathogenic genera (Escherichia, Shigella, Salmonella) and lower autochthonous taxa were identified by LEFSe in pre-LT patients (Fig. 1B) . Despite similar diversity post-LT compared with controls, post LT patients continued to have different microbiota with higher constituents from beneficial Clostridial families (Ruminococcaceae, Lachnospiraceae) and Bifidobacteriaceae. Post-LT patients had increased Bacteroidaceae compared with controls (Fig. 1C) .
COGNITIVE AND HRQOL TESTING
There was a significant improvement in overall PHES score due to all individual scores apart from line-tracing errors in the entire group (delta PHES median, 24; interquartile range [IQR], 8.5). This was accompanied by significantly better HRQOL on SIP (Table 1) . Before LT in the 33 prior HE patients, there was a worse PHES (median 26 versus 22; P 5 0.04) and SIP (total, 31.5 6 19.4 versus 15.9 6 14.1; P 5 0.007; psychosocial, 27.3 6 18.1 versus 14.1 6 18.2; P 5 0.04; and physical, 29.6 6 22.2 versus 9.2 6 9.5; P < 0.001) compared with those without prior HE.
A significant reduction in MHE compared with PHES norms was seen after LT but 35% of patients remained impaired. Of the 26 patients who had MHE on PHES before LT, 15 improved and became MHE-free after LT, 3 improved their score but were still MHE after LT, and 8 had similar to worse PHES score that still qualified as MHE after LT compared with their pre-LT performance. Of the 19 patients who did not have MHE before LT, 14 remained MHE-free with PHES improvement and 5 developed new impairment after LT.
Thirteen (29%) patients did not improve their PHES after LT (delta PHES median, 0; IQR, 2.5) compared with the rest (delta PHES median 26; IQR, 7.25). Therefore, of the 13 who did not improve their PHES after LT, 5 had new-onset cognitive impairment, whereas 8 had continued impairment. Of these 13 patients, 3 had developed infections requiring antibiotics within 3 months of LT, including 2 with biliary sepsis and 2 with C. difficile (1 patient with both infections), 2 underwent elective hernia repairs, and 1 had post-LT delirium.
In patients whose PHES improved after LT, there was a significant improvement (decrease) in total, psychosocial, and physical SIP scores. Conversely, patients without improvement in PHES had similar SIP scores before and after LT (Fig. 2) . NOTE: All data presented as mean 6 SD unless mentioned otherwise. A significant improvement in most cognitive tests and quality of life was seen in the group as a whole, but it is still lower than that of healthy controls even after transplant. A high score on the digit symbol test indicates good performance; the reverse is true for other cognitive tests. *P < 0.05 pretransplant versus posttransplant on paired t test or Wilcoxon matched pairs tests. † P < 0.05 pretransplant compared with controls. ‡ P < 0.05 posttransplant on unpaired t tests or Mann-Whitney U tests.
FIG. 2.
Changes in SIP after transplant based on cognitive improvement. SIP is a validated quality of life questionnaire that has a total score, psychosocial domain (Psych) score, and a physical domain (Phys) score. A high score indicates worse quality of life. The data are presented as median (IQR) with gray bars indicating patients whose cognitive function did not improve after transplant whereas white bars indicate those patients whose cognition improved after transplant. There is a significant improvement (reduction) in SIP scores on total and both domains in patients whose cognitive function improved after transplant (*P < 0.05, pretransplant compared to posttransplant). 
COGNITIVE CHANGE AND MICROBIAL COMPOSITION
In patients whose cognitive function improved after LT, there was a significant reduction in Proteobacteria compared with pre-LT patients (Fig. 3) , which on further analysis was due to reduced Enterobacteriaceae (median pre-LT patients 9% versus 0% post-LT patients; P 5 0.02). There was also a significant increase in Firmicutes relative abundance, which was due to increase in Lachnospiraceae (median pre-LT patients 12% versus post-LT patients 28%; P 5 0.04) at the family level (Fig. 3) . Conversely, a significant increase in relative abundance of Proteobacteria was seen in the patients whose cognitive function did not improve. At the family level, there was an increase in relative Enterobacteriaceae abundance (median pre-LT versus post-LT groups, 0% versus 12%; P 5 0.04). This was also accompanied by a reduction in Firmicutes in these patients. Delta PHES was negatively correlated with delta Proteobacteria (r 5 20.5; P 5 0.05) and positively with delta Firmicutes (r 5 0.6, P 5 0.01), ie, a higher Protebacterial and lower Firmicutes relative abundance change was correlated with lower or worse PHES performance. A multivariate regression using age, sex, pre-LT HE, pre-LT MHE, alcoholic etiology, and Firmicutes and Proteobacteria before LT was performed. The only significant variable that predicted cognitive improvement was absence of pre-LT MHE (hazard ratio [HR], 2.12; P 5 0.03). A subsequent model was created with delta Proteobacteria and delta Firmicutes instead of Proteobacteria and Firmicutes before LT, which demonstrated that both delta Proteobacteria (HR, 1.05; P 5 0.005) and absence of pre-LT MHE (HR, 3.1; P 5 0.05) were associated with cognitive improvement. No impact of other variables, including alcoholic etiology, demographics, and pre-LT HE were found.
Discussion
The study findings indicate that there is improvement in gut microbiota with improved diversity, increase in autochthonous taxa, and reduction in potentially pathogenic taxa within 6 months of LT. We found that although most patients derive cognitive benefit, almost a third remained unchanged cognitively, which was associated with HRQOL impairment. Changes in cognition were associated with changes in Proteobacteria relative abundance after LT.
There is a severe alteration of the gut-liver-brain axis in patients with cirrhosis. (4, 5, 7, 20) The assumption remains that this ameliorates after LT. However, a subset of patients is cognitively impaired even after LT, which can have daily functional and HRQOL implications. (21, 22) Indeed, we found that patients with a lack of cognitive improvement had impaired HRQOL that spanned both physical and psychosocial domains of the SIP. This can be extrapolated into a greater burden on the patients and caregivers despite the LT and portends a poor overall recovery. We found on multivariate regression that pre-LT MHE but not simple HE status was able to predict post-LT cognitive improvement. However, a deeper understanding of the changes in the pathophysiological variables could help define posttransplant changes.
Prior studies have associated pre-LT HE and MHE (cognitive impairment), but a detailed analysis of the gut-liver-brain axis after LT has not been systematically performed. (22) (23) (24) We found that LT, even within 6 months, can significantly improve the diversity of microbiota as a whole. This was accompanied by a   FIG. 3 . Changes in gut microbial phyla after transplant based on cognitive improvement. The major gut microbial phyla, Bacteroidetes (Bact), Firmicutes (Firm), and Proteobacteria (Proteo) are represented as median (IQR) of relative abundance before and after transplant. Gray bars indicate patients whose cognitive function did not improve after transplant whereas white bars indicate those patients whose cognition improved after transplant. There was a significant reduction in Firmicutes and increase in Proteobacteria relative abundance after transplant in patients without cognitive improvement whereas the reverse was seen in those whose cognition improved (*P < 0.05, pretransplant compared with posttransplant). significant reduction in potentially pathogenic taxa and increase in autochthonous ones. After LT, patients are exposed to perioperative antibiotics, immunosuppressive therapy, residual portal hypertension as well as new antifungal, antiviral, and antibiotic agents. (25) These can all impact and potentially confound cognitive status as well as gut microbiota. Indeed prior animal studies have demonstrated that the gut microbiota can play an important role in determining infection as well as rejection risk. (11, 12) Smaller human post-LT studies have also demonstrated changes in the gut microbiota in the perioperative and longterm settings using very focused microbial diagnostic techniques. (9, 10) Our study extends longitudinally in a larger sample size of patients who were free of posttransplant rejection and acute infections and who were stable on tacrolimus, mycophenolate, and trimethoprim-sulfomethoxazole.
Despite the concurrent use of immunosuppressive drugs and antibiotics at the time of the post-LT visit, there were still beneficial changes in microbial diversity as well as individual taxa. This illustrates the key role of the liver in modulating the development and propagation of gut dysbiosis and that a successful transplant can improve this despite concurrent antibiotics and immunosuppression. However, when compared with age-matched healthy controls, despite a statistically similar microbial diversity after LT, there still remained deficits in beneficial gram-positive Clostridial families and Bifidobacteriaceae. This was also seen in the perioperative period in a prior small study. (10) These findings could potentially be related to the concurrent immunosuppression, which can increase endotoxemia early on and impair intestinal permeability. (26) There could be a further improvement with time and our 6-month post-LT timeframe could be a factor in these particular changes. (9) The gut-liver-brain axis is adversely affected in patients with cirrhosis, and our results show that these relationships continue in the post-LT period despite a healthy liver. As expected, most patients improved their cognition and HRQOL after LT. However, in the almost one-third who did not, there was an association of the cognition with relative Proteobacteria and Firmicutes abundance. Proteobacteria, especially the family Enterobacteriaceae, have been long associated with endotoxemia, systemic inflammation, and negative outcomes in cirrhosis and chronic liver disease. (4, 20) Most studies defining cognitive recovery after transplant have focused on pre-LT HE and cognitive status as a predictor of post-LT function. (21, 23, 24) Interestingly, none of pre-LT microbiota had relative abundances, but the change in Proteobacteria was associated with post-LT cognition. Our findings of delta Proteobacteria rather than pre-LT Proteobacteria as independent predictors of post-LT cognitive performance suggest that the posttransplant course may be as relevant as pre-LT events in determining this outcome. (8) A relatively eventful postoperative course with infections, multiple antibiotics, and hospitalizations could affect whether cognitive function improves, remains the same, or deteriorates after transplant. Therefore, it is likely that the relatively higher abundance of Proteobacteria and lower relative abundance in Firmicutes in those with cognitive impairment is likely due to the post-LT events, including infections, immunosuppression use, and antibiotics because all patients had a healthy and functional liver. Infections can alter brain function with and without liver disease. (27) In addition, an altered gut-brain axis in the absence of significant liver disease has been described in autism spectrum disorder and depression and in studies of multiple sclerosis, and HIV members of Proteobacteria are actually found in the brain on autopsy. (28) (29) (30) Because this is a correlative analysis, it is difficult to define whether this is a cause or effect regarding the cognitive function, but this post-LT dysbiosis could contribute toward the continued cognitive impairment in post-LT patients compared with healthy controls. However, focusing on selected patients with lower Firmicutes and higher Proteobacteria after LT for beneficial modulation of the microbiota could be a future step to improve cognition.
The current study is limited by the relatively small number of patients, which limits analysis of subclasses (those with new-onset cognitive impairment compared with those with continuing impairment) from a microbial perspective. We also studied patients at 6 months after LT, and results could be different as patients recover for a longer period or if they are closer to the perioperative period. Our study was completed before HCV eradication became widespread and cognitive and microbial changes before and after LT could be modulated with this approach.
We conclude that after successful LT, there is improvement in gut microbiota diversity and dysbiosis compared with the cirrhotic stage. However, there still remains residual dysbiosis compared with healthy controls. There are cognitive and quality of life improvements in most patients after LT, but in those who have posttransplant cognitive impairment, there is a higher Proteobacteria relative abundance change. Alterations in gut microbiota that are related to a combination of pretransplant and posttransplant events are associated with the ultimate cognitive performance after transplant. Further studies are required to define if beneficial modulation of gut microbiota, especially in patients with multiple posttransplant infections and hospitalizations, could benefit the overall cognitive function in LT recipients.
